Contribute Try STAT+ Today

The most powerful cholesterol drugs ever invented have become a pharmaceutical cautionary tale, failing to reach their commercial potential because of high sticker prices and an inconvenient need for needles. Esperion Therapeutics (ESPR), a small Michigan company with a pair of approved cholesterol treatments, believes it can replicate their effects in pill form, creating a cheaper, easier-to-take medicine that can succeed where its predecessors faltered.

Esperion said Wednesday that it has bought the rights to an oral treatment that targets PCSK9, a protein found in the liver that regulates LDL “bad” cholesterol. The deal, involving a privately held firm called Serometrix, involves a $12.5 million in upfront cash followed by undisclosed future payments tied to development milestones.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • You need better medicines that dont have side effects that make people weak and where you dont have to worry about potassium intake

  • Obviously Esperion is desperate in believing that LDL is a valid biomarker for CVD and mortality. In their first approval, the FDA label specifically marked the drug did not show any benefit for CVD and mortality. So why buy another PCSK9 asset?

Comments are closed.